Diabetes & EndocrinologyMASHpemvidutide
Dual Agonism for MASH: Pemvidutide Achieves Rapid Histological Resolution in Phase 2b IMPACT Trial
By MedXY|Jan 13, 2026
The Phase 2b IMPACT trial demonstrates that pemvidutide, a GLP-1/glucagon dual agonist, significantly achieves MASH resolution at 24 weeks without dose titration, though fibrosis improvement did not reach significance at this early timepoin
